Work

Distinguishing Pseudoprogression From Progression in High-Grade Gliomas

Year: 2013

Type: article

Abstract: We report a case in which 18F-FDG PET was able to discriminate pseudoprogression from progression observed on contrast-enhanced (CE) MRI (CE-MRI). A 56-year-old male patient with anaplastic oligodendroglioma demonstrated markedly increased tumor enhancement on CE-MRI 1 month after completing radiation therapy (RT), suggesting radiological progression. However, the patient was clinically improved and therefore received an early-therapy response assessment PET to assess for pseudoprogression. PET showed low tumor uptake indicating stable disease. Follow-up CE-MRI at 3 and 4 months post-RT confirmed stable disease. This case emphasizes the value of 18F-FDG PET when pseudoprogression is clinically suspected.

Source: Clinical Nuclear Medicine

DOI: 10.1097/rlu.0b013e318286c148

Authors: Matthew J. Oborski, Charles M. Laymon, Frank S. Lieberman, James M. Mountz

Institution: University of Pittsburgh

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute